Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12623000413628
Ethics application status
Approved
Date submitted
7/03/2023
Date registered
26/04/2023
Date last updated
23/06/2024
Date data sharing statement initially provided
26/04/2023
Type of registration
Retrospectively registered
Titles & IDs
Public title
The COPPER Trial: Comparision of a tumour marker in patients with appendix or right sided colon cancer
Query!
Scientific title
COmparison of carcinoembryonic antigen levels between Portal and PERipheral blood in patients with appendiceal or right sided colon cancer (The COPPER Trial)
Query!
Secondary ID [1]
309142
0
Nil known
Query!
Universal Trial Number (UTN)
U1111-1289-4006
Query!
Trial acronym
The COPPER trial (COmparison of carcinoembryonic antigen levels between Portal and PERipheral blood in patients with appendiceal or right sided colon cancer)
Query!
Linked study record
Nil known
Query!
Health condition
Health condition(s) or problem(s) studied:
Appendiceal cancer
329242
0
Query!
Colon cancer
329243
0
Query!
Condition category
Condition code
Cancer
326199
326199
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Cancer
326200
326200
0
0
Query!
Other cancer types
Query!
Blood
326201
326201
0
0
Query!
Other blood disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The only intervention will be to take five ml of blood will be taken from a vein in the patient's arm (this will be from a intravenous cannula as part of the patient's general anaesthetic such that there will be no additional venepuncture burden) as well as another 5 ml of blood from the ileocolic / appendicular vein (a blood vessel that drains blood from the appendix or right colon that is located in the right lower side of the abdomen) during the initial stages of your peritonectomy surgery (total number of blood tests: 2; total volume: 10ml; NB: 5-10mL is equivalent to 1-2 teaspoons). The blood sampling would take less than one minute during surgery by the anaesthetist (peripheral sample) and the surgeon (portal vein sample). Assessment of the fidelity of this intervention will be in part by testing for albumin of these specimens for comparison.
Query!
Intervention code [1]
325591
0
Diagnosis / Prognosis
Query!
Intervention code [2]
325646
0
Early detection / Screening
Query!
Intervention code [3]
325647
0
Treatment: Other
Query!
Comparator / control treatment
Portal vein carcino-embryonic antigen (CEA) and peripheral vein CEA from appendiceal cancer patients will be compared as will those CEA levels from right sided colon cancer patients. We intend to note if one group or the other or neither or both have any significant differences between the portal vein and peripheral vein CEA levels. Peripheral vein CEA will be the comparator with albumin taken at the same time for quality assessment comparisons between specimens as a reference range
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
334077
0
Carcinoembryonic antigen (CEA) levels determined from the portal vein
Query!
Assessment method [1]
334077
0
Query!
Timepoint [1]
334077
0
Blood samples to be collected during surgery
Query!
Primary outcome [2]
334202
0
Carcinoembryonic antigen (CEA) levels determined from the peripheral vein
Query!
Assessment method [2]
334202
0
Query!
Timepoint [2]
334202
0
Blood samples to be collected during surgery
Query!
Primary outcome [3]
334203
0
Albumin levels determined from the peripheral and portal vein as a composite primary outcome for correlation..
Query!
Assessment method [3]
334203
0
Query!
Timepoint [3]
334203
0
Blood samples to be collected during surgery
Query!
Secondary outcome [1]
419288
0
Immunohistochemical and histopathological (i.e., differentiation, node metastasis, lymphovascular invasion, etc) variables of the primary appendiceal and right sided colon cancer by NSW Health pathology as part of routine histopathological reporting - Composite secondary outcomes
Query!
Assessment method [1]
419288
0
Query!
Timepoint [1]
419288
0
Tumour samples to be collected during surgery
Outcomes measured throughout hospital stay and during outpatient follow-up and surveillance, e.g., 6- and 12-monthly post-surgery follow-up then yearly for 5 years
Query!
Eligibility
Key inclusion criteria
* Sex: All
* Age range: 18 years and above
* Disease status: Appendiceal or right sided colon cancer (suspected or confirmed)
* Willingness to give written informed consent and willingness to participate to and comply with the study.
* Pre-operative carcino-embryonic antigen (CEA) level > 5 microg/L
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Participants who cannot provide informed consent.
* Patients who have had a previous peritonectomy (including those who have previously undergone a right hemicolectomy).
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Nil known
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Nil known
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Nil known
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Based on the Tabuchi et al, study, mean CEA level for portal vein samples were 26.6 ± 6.4 ng/mL and 8.1 ± 1.9 ng/mL for peripheral vein samples.1 Using these values, an enrollment ratio of 1, alpha value of 0.05, power set to 90%, with a continuous endpoint, as a two independent sample study, the estimated total sample size is 6 patients.2
1. TABUCHI, Y ET AL. “COMPARISON OF CARCINOEMBRYONIC ANTIGEN LEVELS BETWEEN PORTAL AND PERIPHERAL BLOOD IN PATIENTS WITH COLORECTAL CANCER. CORRELATION WITH HISTOPATHOLOGIC VARIABLES.” CANCER VOL. 59,7 (1987): 1283-8. DOI:10.1002/1097-0142(19870401)59:7<1283::AID-CNCR2820590709>3.0.CO;2-G
2. ROSNER B. FUNDAMENTALS OF BIOSTATISTICS. 7TH ED. BOSTON, MA: BROOKS/COLE; 2011.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/07/2022
Query!
Date of last participant enrolment
Anticipated
19/07/2029
Query!
Actual
Query!
Date of last data collection
Anticipated
19/08/2029
Query!
Actual
Query!
Sample size
Target
15
Query!
Accrual to date
8
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
24212
0
St George Hospital (QLD) - St George
Query!
Recruitment postcode(s) [1]
39745
0
4487 - St George
Query!
Funding & Sponsors
Funding source category [1]
313343
0
Hospital
Query!
Name [1]
313343
0
St George Hospital Fund
Query!
Address [1]
313343
0
Department of Surgery
St George Hospital
Pitney Building
Short street
KOGARAH NSW 2217
Australia
Query!
Country [1]
313343
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
Professor David Morris
Query!
Address
Department of Surgery
St George Hospital
Pitney Building
Short street
KOGARAH NSW 2217
Australia
Query!
Country
Australia
Query!
Secondary sponsor category [1]
315091
0
None
Query!
Name [1]
315091
0
Query!
Address [1]
315091
0
Query!
Country [1]
315091
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
312565
0
South Eastern Sydney Local Health District HREC
Query!
Ethics committee address [1]
312565
0
District Executive Unit, Level4
The Sutherland Hospital & Community Health Service
Cnr The Kingsway & Kareena Road
Caringbah
NSW
2229
Query!
Ethics committee country [1]
312565
0
Australia
Query!
Date submitted for ethics approval [1]
312565
0
20/04/2022
Query!
Approval date [1]
312565
0
06/05/2022
Query!
Ethics approval number [1]
312565
0
Query!
Summary
Brief summary
The purpose of this study is to explore the differences in a type of tumour marker, called a carcinoembryonic antigen, in two different blood sample sites.
Who is it for?
You may be eligible for this study if you are an adult who has been diagnosed with cancer of either the colon or appendix.
Study details
All participants in this study will be asked to provide consent for venous blood samples to be taken as part of your peritonectomy surgery. Five ml of blood will be taken from a vein in your arm as well as another 5 ml of blood from the vein near your appendix or right colon that is located in the right lower side of the abdomen during the initial stages of your peritonectomy surgery.
All participants will also give access to medical records to collect the relevant study data such as demographic details, diagnosis, treatment, blood and histopathological results.
It is hoped that this research will form part of the eventual outcome where we hope to identify patients at risk of developing liver metastases from their colorectal cancer and develop a suitable drug to prevent these patients from developing liver metastases - Improving their prognosis and disease free survival.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
125110
0
Dr Adam Cristaudo
Query!
Address
125110
0
St George Hospital, Gray St, Kogarah NSW 2217.
Query!
Country
125110
0
Australia
Query!
Phone
125110
0
+61 02 9113 2070
Query!
Fax
125110
0
Query!
Email
125110
0
[email protected]
Query!
Contact person for public queries
Name
125111
0
Dr Adam Cristaudo
Query!
Address
125111
0
St George Hospital, Gray St, Kogarah NSW 2217.
Query!
Country
125111
0
Australia
Query!
Phone
125111
0
+61 02 9113 2070
Query!
Fax
125111
0
Query!
Email
125111
0
[email protected]
Query!
Contact person for scientific queries
Name
125112
0
Dr Adam Cristaudo
Query!
Address
125112
0
St George Hospital, Gray St, Kogarah NSW 2217.
Query!
Country
125112
0
Australia
Query!
Phone
125112
0
+61 02 9113 2070
Query!
Fax
125112
0
Query!
Email
125112
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Patient age, sex, peripheral and portal vein CEA levels, characteristics of tumour and operation - all deidentified
Query!
When will data be available (start and end dates)?
Start date: 6/5/2022 (in line with ethical approval); No end date, available for 5 years after publication
Query!
Available to whom?
individual participant data will only be available to those who access all future publications and presentations - deidentified
Query!
Available for what types of analyses?
For research purposes only - deidenitified
Query!
How or where can data be obtained?
individual participant data will only be available to those who access all future publications and presentations - deidentified
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
18522
Informed consent form
385513-(Uploaded-07-03-2023-11-59-01)-Study-related document.doc
18523
Study protocol
385513-(Uploaded-07-03-2023-11-59-15)-Study-related document.docx
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Dimensions AI
Comparison Of carcinoembryonic antigen levels between Portal and PERipheral blood in patients with appendiceal adenocarcinoma (COPPER) trial
2024
https://doi.org/10.1093/bjs/znae052
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF